FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142364508> ?p ?o ?g. }

• W2142364508 endingPage "261" @default.
• W2142364508 startingPage "252" @default.
• W2142364508 abstract "Abstract The orally bioavailable rapamycin derivative RAD001 (everolimus) targets the mammalian target of rapamycin pathway and possesses potent immunosuppressive and anticancer activities. Here, the antitumor activity of RAD001 was evaluated in the CA20948 syngeneic rat pancreatic tumor model. RAD001 demonstrated dose-dependent antitumor activity with daily and weekly administration schedules; statistically significant antitumor effects were observed with 2.5 and 0.5 mg/kg RAD001 administered daily [treated tumor versus control tumor size (T/C), 23% and 23–30%, respectively], with 3–5 mg/kg RAD001 administered once weekly (T/C, 14–36%), or with 5 mg/kg RAD001 administered twice weekly (T/C, 36%). These schedules were well tolerated and exhibited antitumor potency similar to that of the cytotoxic agent 5-fluorouracil (T/C, 23%). Moreover, the efficacy of intermittent treatment schedules suggests a therapeutic window allowing differentiation of antitumor activity from the immunosuppressive properties of this agent. Detailed biochemical profiling of mammalian target of rapamycin signaling in tumors, skin, and peripheral blood mononuclear cells (PBMCs), after a single administration of 5 mg/kg RAD001, indicated that RAD001 treatment blocked phosphorylation of the translational repressor eukaryotic initiation factor 4E-binding protein 1 and inactivated the translational activator ribosomal protein S6 kinase 1 (S6K1). The efficacy of intermittent treatment schedules was associated with prolonged inactivation of S6K1 in tumors and surrogate tissues (≥72 h). Furthermore, detailed analysis of the dose dependency of weekly treatment schedules demonstrated a correlation between antitumor efficacy and prolonged effects (≥7 days) on PBMC-derived S6K1 activity. Analysis of human PBMCs revealed that S6K1 also underwent a concentration-dependent inactivation after RAD001 treatment ex vivo (&gt;95% inactivation with 20 nm RAD001). In contrast, human PBMC-derived eukaryotic initiation factor 4E-binding protein 1 was present predominantly in the hypophosphorylated form and was unaffected by RAD001 treatment. Taken together, these results demonstrate a correlation between the antitumor efficacy of intermittent RAD001 treatment schedules and prolonged S6K1 inactivation in PBMCs and suggest that long-term monitoring of PBMC-derived S6K1 activity levels could be used for assessing RAD001 treatment schedules in cancer patients." @default.
• W2142364508 created "2016-06-24" @default.
• W2142364508 creator A5002553364 @default.
• W2142364508 creator A5006648565 @default.
• W2142364508 creator A5010632648 @default.
• W2142364508 creator A5030178833 @default.
• W2142364508 creator A5030877547 @default.
• W2142364508 creator A5034438379 @default.
• W2142364508 creator A5036217163 @default.
• W2142364508 creator A5036570612 @default.
• W2142364508 creator A5038355320 @default.
• W2142364508 creator A5075810252 @default.
• W2142364508 creator A5082438939 @default.
• W2142364508 creator A5084022982 @default.
• W2142364508 creator A5085680989 @default.
• W2142364508 date "2004-01-01" @default.
• W2142364508 modified "2023-10-18" @default.
• W2142364508 title "Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells" @default.
• W2142364508 cites W1021684886 @default.
• W2142364508 cites W1501966284 @default.
• W2142364508 cites W1569415412 @default.
• W2142364508 cites W1585385265 @default.
• W2142364508 cites W1597228305 @default.
• W2142364508 cites W1963723155 @default.
• W2142364508 cites W1965772972 @default.
• W2142364508 cites W1969498816 @default.
• W2142364508 cites W1978625554 @default.
• W2142364508 cites W1979770710 @default.
• W2142364508 cites W1982558191 @default.
• W2142364508 cites W1987105275 @default.
• W2142364508 cites W1988609792 @default.
• W2142364508 cites W1993836723 @default.
• W2142364508 cites W1998839324 @default.
• W2142364508 cites W2001881651 @default.
• W2142364508 cites W2002031023 @default.
• W2142364508 cites W2006559495 @default.
• W2142364508 cites W2006797658 @default.
• W2142364508 cites W2006874274 @default.
• W2142364508 cites W2008239768 @default.
• W2142364508 cites W2008294451 @default.
• W2142364508 cites W2008800889 @default.
• W2142364508 cites W2011282245 @default.
• W2142364508 cites W2011485783 @default.
• W2142364508 cites W2012142261 @default.
• W2142364508 cites W2015174638 @default.
• W2142364508 cites W2023012828 @default.
• W2142364508 cites W2026351725 @default.
• W2142364508 cites W2028549543 @default.
• W2142364508 cites W2035016947 @default.
• W2142364508 cites W2046056542 @default.
• W2142364508 cites W2048498664 @default.
• W2142364508 cites W2056137479 @default.
• W2142364508 cites W2072057417 @default.
• W2142364508 cites W2079537922 @default.
• W2142364508 cites W2082853003 @default.
• W2142364508 cites W2085841899 @default.
• W2142364508 cites W2089668045 @default.
• W2142364508 cites W2089869923 @default.
• W2142364508 cites W2090407808 @default.
• W2142364508 cites W2097731453 @default.
• W2142364508 cites W2102648794 @default.
• W2142364508 cites W2105516763 @default.
• W2142364508 cites W2111941775 @default.
• W2142364508 cites W2124587511 @default.
• W2142364508 cites W2137855766 @default.
• W2142364508 cites W2139856846 @default.
• W2142364508 cites W2142506125 @default.
• W2142364508 cites W2144059623 @default.
• W2142364508 cites W2150178760 @default.
• W2142364508 cites W2151811858 @default.
• W2142364508 cites W2160079255 @default.
• W2142364508 cites W2163382569 @default.
• W2142364508 cites W2163583831 @default.
• W2142364508 cites W31017647 @default.
• W2142364508 doi "https://doi.org/10.1158/0008-5472.can-3554-2" @default.
• W2142364508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14729632" @default.
• W2142364508 hasPublicationYear "2004" @default.
• W2142364508 type Work @default.
• W2142364508 sameAs 2142364508 @default.
• W2142364508 citedByCount "309" @default.
• W2142364508 countsByYear W21423645082012 @default.
• W2142364508 countsByYear W21423645082013 @default.
• W2142364508 countsByYear W21423645082014 @default.
• W2142364508 countsByYear W21423645082015 @default.
• W2142364508 countsByYear W21423645082016 @default.
• W2142364508 countsByYear W21423645082017 @default.
• W2142364508 countsByYear W21423645082018 @default.
• W2142364508 countsByYear W21423645082019 @default.
• W2142364508 countsByYear W21423645082020 @default.
• W2142364508 countsByYear W21423645082021 @default.
• W2142364508 countsByYear W21423645082022 @default.
• W2142364508 countsByYear W21423645082023 @default.
• W2142364508 crossrefType "journal-article" @default.
• W2142364508 hasAuthorship W2142364508A5002553364 @default.
• W2142364508 hasAuthorship W2142364508A5006648565 @default.
• W2142364508 hasAuthorship W2142364508A5010632648 @default.
• W2142364508 hasAuthorship W2142364508A5030178833 @default.
• W2142364508 hasAuthorship W2142364508A5030877547 @default.

• next